BlueCross BlueShield Federal Employee Program

MOTEGRITY (prucalopride)

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Motegrity (prucalopride) is a selective serotonin type 4 (5-HT4) receptor agonist. It is a gastrointestinal (GI) prokinetic agent that stimulates colonic peristalsis (high-amplitude propagating contractions), which increases bowel motility (1).

Regulatory Status

FDA-approved indication: Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults (1).

The use of this medication is contraindicated in patients with intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum (1).

Motegrity may cause an increase in suicidal ideation and behavior. All patients should be monitored for persistent worsening of depression or the emergence of suicidal thoughts and behaviors. Patients, caregivers, and family members of patients should be counseled to be aware of any unusual changes in mood or behavior and alert the healthcare provider (1).

The safety and effectiveness of Motegrity in pediatric patients less than 18 years of age have not been established (1).

Summary

Motegrity (prucalopride) is a selective serotonin type 4 (5-HT4) receptor agonist. It is a gastrointestinal (GI) prokinetic agent that stimulates colonic peristalsis (high-amplitude propagating contractions), which increases bowel motility. The safety and effectiveness of Motegrity in pediatric patients less than 18 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Motegrity while maintaining optimal therapeutic outcomes.

References

1. Motegrity [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November 2020.